Skin treatment apparatus for personal use and method for using same

Information

  • Patent Grant
  • 9504826
  • Patent Number
    9,504,826
  • Date Filed
    Wednesday, July 6, 2011
    13 years ago
  • Date Issued
    Tuesday, November 29, 2016
    8 years ago
Abstract
An apparatus for personal skin treatment includes an RF generator and an applicator with at least a pair of electrodes mounted on the distal end of the applicator. The electrodes are configured for applying an RF voltage to a subject skin. The RF voltage generator supplies the electrodes with the RF voltage. The applicator includes a source of illumination illuminating the treated skin segment.
Description
TECHNOLOGY FIELD

The method and apparatus are related to the field of personal cosmetic procedures and in particular to wrinkle removal procedures.


BACKGROUND

External appearance is important to most people. In recent years, methods and apparatuses have been developed for different cosmetic treatments. Among these are hair removal, treatment of vascular lesions and skin rejuvenation. In these treatments, a volume of skin tissue under the skin is heated to a temperature that is sufficiently high as to achieve a desired skin effect. The temperature producing the desired effect is typically in the range of 38-60 degrees Celsius. One method that has been used for heating the epidermal and dermal layers of the skin is pulsed or continuous radio-frequency (RF) energy. In this method, electrodes are applied to the skin and an RF voltage pulse is applied across the electrodes. The properties of the voltage pulse are selected so as to generate an RF current pulse which heats the tissue to the required temperature.


Presently, a number of light based skin surface or deeper skin layer treatments have been developed. These treatments typically use laser diodes, LED, Xenon lamp (Intense Pulsed Light or IPL) or incandescent lamp radiation to irradiate a surface of skin where vascular lesions, varicose veins, acne, mole marks and similar disorders are present. The optical radiation may have a single wavelength or several wavelengths. The wavelengths are selected to be optimal for the color of the contrasted component of the target skin segment, and are typically in the range of 400 to 1800 nm.


The above described equipment is both costly and bulky. It is typically operated in an ambulatory set-up by a qualified operator and frequently requires the presence of medical personnel specialized in such treatments. There is a need on the market for a small size, low cost, and safe to use apparatus that may be operated by the user and enable the user to use the equipment and get results similar or identical to those achieved by professional equipment skin treatments.


BRIEF SUMMARY

An apparatus for personal cosmetic skin treatment including an RF generator and an applicator with at least a pair of electrodes mounted on the distal end of the applicator. The electrodes are configured for applying an RF voltage to a subject skin. The RF generator is configured to supply a number of RF voltage types to the electrodes. A source of light is arranged between electrodes and illuminates the skin segment between the electrodes. The applicator is moved over the skin in a scanning movement applying RF voltage to the segment of skin between the electrodes. The source of light operates concurrently or sequentially with the RF generator and illuminates the same segment of skin.





BRIEF LIST OF DRAWINGS

The apparatus and the method are particularly pointed out and distinctly claimed in the concluding portion of the specification. The apparatus and the method, however, both as to organization and method of operation, may best be understood by reference to the following detailed description when read with the accompanying drawings, in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the method.



FIGS. 1A and 1B, jointly referred to as FIG. 1, are schematic illustrations of an exemplary embodiment of the apparatus for personal skin treatment.



FIG. 2 is a schematic illustration of a cross section along the longitudinal axis of an exemplary embodiment of the applicator of the apparatus of FIG. 1.



FIG. 3 is a schematic three-dimensional illustration of an exemplary embodiment of a distal end of the applicator.



FIGS. 4A and 4
b, jointly referred to as FIG. 4, are schematic illustrations of some exemplary electrode-thermocouple configurations of the applicator.



FIGS. 5A, 5B and 5C, jointly referred to as FIG. 5, are schematic illustrations of some additional exemplary applicator electrode configurations.



FIG. 6 is a schematic illustration of a cross section of the applicator of FIG. 1 in plane perpendicular to longitudinal axis of the applicator.



FIG. 7 is a schematic illustration of an applicator with a built-in gel dispenser.



FIG. 8 is a schematic illustration of a cross section of the docking stand of the apparatus for skin treatment.



FIG. 9 is a schematic illustration of an exemplary embodiment of the electronic circuit of the apparatus for skin treatment.



FIG. 10 is a schematic illustration of another exemplary embodiment of the electronic circuit of the apparatus for skin treatment.



FIG. 11 is a schematic illustration of an additional exemplary embodiment of the electronic circuit of the apparatus for skin treatment.



FIG. 12 is a schematic illustration of an additional embodiment of the apparatus for personal skin treatment.



FIG. 13 is a schematic illustration of a further embodiment of an apparatus for personal skin treatment with a built-in gel dispensing arrangement.



FIG. 14 is a schematic illustration of typical skin treatment scanning movements of the applicator.





DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS

In the following detailed description, reference is made to the accompanying drawings which form a part hereof. This is shown by way of illustrating different embodiments in which the apparatus and method may be practiced. Because components of embodiments of the present apparatus can be positioned in a number of different orientations, the directional terminology is used for purposes of illustration and is in no way limiting. It is to be understood that other embodiments may be utilized and structural or logical changes may be made without departing from the scope of the present method and apparatus. The following detailed description, therefore, is not to be taken in a limiting sense, and the scope of the present apparatus and method is defined by the appended claims.


As used herein, the term “skin treatment” includes cosmetic skin treatment of various skin layers such as stratum corneum, dermis, epidermis, skin rejuvenation procedures, wrinkle removal, and such procedures as collagen shrinking or destruction. The term “skin surface” relates to the most external skin layer, which may be stratum corneum.


Reference is made to FIG. 1, which is a schematic illustration of an exemplary embodiment of the apparatus for personal skin treatment. Apparatus 100 (FIG. 1A) comprises an applicator 104 adapted for sliding movement on a subject skin, a docking stand 108 on which the applicator is placed when not in use (FIG. 1B) and harness 112 connecting applicator 104 and stand 108. Harness 112 enables electric or other type of communication between applicator 104 and stand 108. When not in operation, applicator 104 may be located in a docking bay 116 (FIG. 1B) of stand 108. Apparatus 100 may receive power supply from a regular electric supply network receptacle, or from a rechargeable or regular battery. Lamp 118 indicates operational status of stand 108.



FIG. 2 is a schematic illustration of a cross section along the longitudinal axis of the applicator of the present apparatus. Applicator 104 is shown to have body or handle, ergonomically shaped or suitably shaped for holding with the hand, and having a longitudinal axis 120 with extending and projecting forward distal end 124 and a proximal end 128. Distal end 124 is typically oriented at an angle α degrees to axis 120. Angle α is selected to enable proper contacts between electrodes 132 and a target area of skin or material to be treated, and at an angle to facilitate convenience in holding applicator 104. For instance, the angle α may be about 110 degrees. Mounted on distal end 124 of the applicator 104 are one or more RF applying electrodes 132 connected through harness 112 to a source of RF voltage (not shown) located in stand 108. An optical filter 136 serves as a mounting basis for electrode 132. Optical filter 136 also serves as an operation indicator of applicator 104. Optical filter 136 is typically a broadband glass or plastic filter that transmits red and infrared wavelength and typically lights with a reddish or first color.


Mounted at the distal end 124 of applicator 104 is a source of light 140 that may be an incandescent lamp 144 or an incandescent lamp optimized (doped) for emission of red and infrared radiation. The useful spectrum of lamp 144 may be in the range of 400 to 1800 nm and emitted optical energy in the range of 1W to 20W. A reflector 148 collects and directs radiation emitted by lamp 144 towards a segment of skin to be treated. Alternatively, an LED emitting one or more suitable wavelengths or a semiconductor laser may be used instead of lamp 144. When LEDs are used as radiation emitting sources their wavelengths may be selected such that one of them will serve as an operation indicator of first color canceling the need for a special filter. The remaining LEDs may provide the wavelengths required for the treatment. A single LED with multiple emitters may also be used. Shown is a magnetic or a ferromagnetic insert 188 cooperating with magnet 208 (FIG. 8) and holding applicator 104 in docking bay 116 (FIGS. 1 and 8) of stand 108.



FIG. 3 is a schematic three-dimensional illustration of an exemplary embodiment of the distal end 124 of applicator 104. FIG. 3 illustrates electrodes 132 mounted on filter 136, thermocouple 160 built-in into at least one of the electrodes 132, and lamp holder 146. Electrodes 132 typically have an elongated body with width 152 to length 156 ratio of at least 1:5. The geometry of the electrodes is optimized to selectively heat the skin in the area between the electrodes. Electrodes 132 typically have rounded edges in order to avoid hot spots on the skin surface near the edges of the electrodes. Rounded electrodes also allow smooth movement of applicator 104 (FIG. 1) over the skin surface. FIG. 3 illustrates a bi-polar electrode system, although a uni-polar electrode system (not shown) may be used. Alternatively, when more than one electrode 132 is used the bi-polar or uni-polar system may be generated by feeding a proper RF voltage to the electrodes.



FIG. 4 is a schematic illustration of some electrode-thermocouple configurations of the applicator. In the embodiment illustrated in FIG. 4A, one or more electrodes 132 may have a built-in thermocouple 160 residing with the temperature-sensing end 168 inside electrode body 132. In another embodiment, shown in FIG. 4B, the temperature-sensing end 168 of thermocouple 160 may be flush with electrode 132 contacting skin surface 164. In some embodiments a thermistor may be used instead of the thermocouple. The thermistor may be embedded into one or more electrodes, or as a standalone probe being in contact with the treated skin segment. Thermocouple 160 having a temperature sensing end flush with electrode 132 surface 164 measures skin temperature, where residing within electrode 132 end of thermocouple 160 measures only electrode 132 temperature. Thermocouple 160 communicates the measured temperature to a feedback loop of RF voltage generator 200 (FIG. 8). Based on temperature values, RF voltage generator 200 may increase or decrease RF voltage amplitude, change the duty cycle of the RF voltage supplied to electrodes 132, or even switch off the RF voltage generator.



FIG. 5 is a schematic illustration of some electrode configurations of applicator 104. In one embodiment (FIG. 5A), electrode 132 is a solid electric current conducting body. In another embodiment (FIG. 5B), electrode 134 may be a flexible electric current conducting body. A flexible electrode is capable of adapting its shape to the contours of the treated subject skin enabling a better contact with the skin. In an additional embodiment (FIG. 5C), electrode 138 may have a relief 166 on the skin contacting surface 164. The relief may be a plurality of microelectrodes or a plurality of macro electrodes.



FIG. 6 is a schematic illustration of a cross section of the applicator of FIG. 1 in plane perpendicular to longitudinal axis of the applicator. It further demonstrates the construction of light source 140. Lamp 144 and reflector 148 are located between electrodes 132. Filter 136 protects lamp 144 and cuts out of the lamp emission a desired spectral range out of a spectrum emitted by lamp 144. The listed elements are assembled on a type of printed circuit board support 150. The illustrated embodiment also shows the inclusion of an optional accelerometer 184.


In order to improve the coupling of RF induced current to the skin 172 (see FIG. 7) it is desirable to cover skin 172 by a layer of gel 176 improving electric contact between electrodes 132 and skin 172 and facilitating electrode on skin gliding. Typically, gel 176 is dispensed over skin 172 before the treatment, and remains on the skin during the treatment. Gel dispensing, in addition to skin cleaning performed by water and soap or other cleaning means, represents a skin pretreatment operation. According to one embodiment, gel 176 may be dispensed manually. A disposable flexible container actuated manually by the user squeezes and dispenses gel 176 over skin 172. In a further embodiment, gel dispenser 180 may be a part of applicator 104 and is actuated automatically during treatment from a disposable or refillable container. Alternatively, gel dispenser may be located in stand 108. Where gel dispenser is located in stand 108, harness 112 (FIG. 1) in addition to electrical lines may contain a suitable tubing for supplying gel 176 to distal end 124 of applicator 104 and skin 172. In order to enable good contact and facilitate the treatment gel 172 may have an electrical resistance higher than the skin being treated.


Applicator 104 may include an accelerometer 184, similar to the accelerometer of FIG. 6, which could detect and provide an indication of the movement of applicator 104 and the speed of the movement. Accelerometer 184 communicates with RF voltage generator 200 (see FIG. 8). Based on the changes in the speed of advance (acceleration) of applicator 104, RF voltage generator 200 may increase or decrease RF voltage amplitude or change the duty cycle of the RF voltage supplied to electrodes 132, enabling optimal maintenance of the treatment temperature.



FIG. 8 is a schematic illustration of a cross section of the docking stand of the apparatus for providing skin treatment. Stand 108 may be an aesthetic looking plastic or metal enclosure 196 incorporating an RF voltage generator 200, an operation indicator 118, and a permanent or electric magnet 208 for holding or securing the applicator 104 with in the docking stand at a particular position. In some embodiments, the RF voltage generator may be located in the applicator 104. Operation indicator 118 may be a lamp similar to lamp 118 having a second color different from the first color of lamp 144. Operation indicator 118 may also serve as a stand-by mode indicator. The lamp or a LED providing the second color may be greenish or bluish. A glass or plastic filter may be used so that a simple incandescent lamp can be used as an indicator. Stand 108 may receive power supply from a regular electric network receptacle with the help of power cord 222 or be equipped by rechargeable batteries.


RF voltage generator 200 has at least one feedback loop operated by a signal received from thermocouple 160 (see FIG. 4). The same or an additional feedback loop may be operated, as explained above, by a signal provided by accelerometer 184 (see FIG. 3 and FIG. 6). Alternatively, the impedance of the treated skin segment may be monitored and used for Automatic RF Power Control (APC). It is known that RF generator output depends on the load. It is desirable to maintain the load flat or uniform during operation. This is, however, possible only in a certain range of treated skin impedance and it may be desirable to operate apparatus 100 in a mode that minimizes skin impedance changes. It is also known that skin parameters vary widely between different treated subjects. A typical range of impedance changes may be from 50 to 400 ohm. (It is necessary to mention that electrode configuration may affect impedance range.) Even for the same person, the impedance of the skin located proximate to the forehead and cheek may be substantially different. The type of contact between the electrodes and skin also affects impedance value. An electrode may contact the skin with its entire surface or only partially, depending on skin relief of the face segment. The feedback loops, and in particular the impedance-based loop, allows constant RF power output to be maintained for all the range of skin impedances. Practically, the impedance of the treated skin segment is constantly monitored and the RF power is adjusted accordingly.



FIG. 9 is a schematic illustration of an exemplary embodiment of the electronic circuit of the apparatus 100 for skin treatment. Typically, the treated subject is isolated from the Earth of power supply network. When both RF electrodes are applied to the skin of the subject, the skin, being a conductor, short circuits the electrodes and provides a pass for the RF induced current. Conductive gel that has a resistance higher than the skin facilitates this current pass. In this particular implementation, one of the electrodes is connected to the ground through an inductor L3. The resulting bi-polar RF electrodes create a zero potential at one electrode while the other electrode relative to ground is at maximum potential.



FIG. 10 is a schematic illustration of another exemplary embodiment of the electronic circuit of the apparatus for skin treatment. This particular embodiment discloses a design where RF electrodes are not grounded at all. When the RF electrodes touch the subject skin, an RF current flows through the skin between the electrodes. The bipolar RF electrodes create a minimum potential between them in the middle, regardless of the potential of the subject with respect to ground.



FIG. 11 is a schematic illustration of an additional exemplary embodiment of the electronic circuit of the apparatus for skin treatment. In this case, the output RF generator stage contains a transformer with a secondary center tap connected to ground-earth through an inductor L3. This enables a zero potential to be obtained relative to ground in the middle of the span between the electrodes.


All of the above disclosed electronic schemes enable supply of the required RF power to the electrodes and avoid subject electric shock even if the subject is in contact with the Earth.



FIG. 12 is a schematic illustration of an additional embodiment of the apparatus for personal skin treatment. Apparatus 250 is a convenient-to-hold body 254 incorporating the applicator and stand elements. Apparatus 250 may be plugged into a conventional electric power supply network or be battery operated. The battery may be rechargeable. All earlier described apparatus 100 (FIG. 1) components are mutatis mutandis applicable to apparatus 250. Operation of apparatus 250 is similar to operation of apparatus 100. When the RF electrodes touch the subject skin, apparatus 250 is activated and an RF induced current flows through the skin between the electrodes. When there is no contact between the electrodes and the skin apparatus 250 is in stand-by mode. Optionally, apparatus 250 may have an ON-OFF switch to switch it off completely.



FIG. 13 is a schematic illustration of a further embodiment of an apparatus for personal skin treatment with built-in gel dispensing arrangement. According to one embodiment, apparatus 290 may have a receptacle for a disposable flexible gel container 294. The gel may be dispensed over the skin manually by application of pressure to container 294. In a further embodiment, gel dispenser (not shown) may be a part of apparatus 290 or a type of an automatic dispenser, which pulls gel required for the treatment out of a disposable or refillable container.


The method of skin treatment using the present apparatus will be explained now. Following cleaning and gel spreading over a target segment of skin 172, applicator 104 is placed over the skin segment 172 such that electrodes 132 are in contact with skin 172. Practically, the skin 172 becomes a conductor automatically closing the circuit and enabling an RF current passage between electrodes 132. Induced by RF voltage, current passes through skin 172 and heats it to a desired temperature. RF voltage is applied to electrodes 132 in a continuous or quasi-continuous mode and with duration of at least 0.5 second.



FIG. 14 is a schematic illustration of typical skin treatment scanning movements of the applicator. Applicator 104 may be moved in a type of reciprocal scanning motion as shown by arrows 300 over the skin 172 to treat next skin segment 312. In the course of movement of the applicator it maintains contact between electrodes 132 and skin 172 and delivers a continuous RF power inducing current to treated skin segments 304-312 located between electrodes 132.


Applicator 104 (or apparatus 250) is displaced over the skin segment to be treated so that RF induced current heats the treated skin segment to a temperature that produces the desired treatment of the skin, for example, stimulating the process of collagen remodeling in the skin. Typically, the RF power applied across electrodes 132 can range from 1 W to 20 W but, it is anticipated that other values and ranges may also be applied. The RF power is applied in a continuous or quasi-continuous mode for a period of time, such as at least 0.5 second as a non-limiting example. Applied in this mode, RF power is capable of heating skin from a normal skin temperature to a temperature of about 60 degrees Celsius. It should be noted that the typical treatment time per skin segment is based on several factors. One such factor is the characteristics of the treated skin segment. For example, a bony area with thin skin, like the forehead (segment 304) versus thicker skin in a non-bony segment, such as the area around the eyes (segment 308);. Another factor includes the average surface area per segment. For example, each cheek, jaw line and chin area (segment 312) will require more time than any of the other areas, each of which is effectively smaller than segment 312. In an exemplary treatment process it may be desirable to spend the necessary time on each treatment zone until the desirable treatment end-point is reached. The treatment end-point may be characterized among others by erythema and a significant heat sensation with possible edema and a tightening feeling. The treatment may be continued for an additional 1-2 minutes stabilizing the treatment effect.


During treatment, skin and electrode temperature sensors or acceleration sensors, or impedance monitoring provide an input to the feedback loops of RF voltage generator 200 (see FIG. 8). Based on input of at least one of the sensors feedback, the RF power automatically changes providing and maintaining optimal treatment conditions. The RF voltage changes may include amplitude changes, voltage application time changes or voltage application duty cycle changes. For example, upper and lower treatment temperature limits may be set. If the feedback indicates that the first or upper temperature limit, which may be set for skin temperature exceeding 44 degrees Celsius, automatic reduction in RF power or change of the applied RF power duty cycle may take place. The duty cycle may be reduced to 60% of the maximal operating value. A complete switch-off of the RF power at a second or upper temperature limit, for example at temperature exceeding 45 degrees Celsius may take place. The RF power may also be changed in response to changes in the scanning speed of the applicator 104 as reported or determined by signals received from accelerometer 184. Despite certain RF power reduction, the treatment may continue because, in order to get proper treatment results, it is desired not only to reach a certain temperature in the tissue, but to maintain it for some threshold period of time. To satisfy this requirement, the decrease in RF power may not exceed 30% or 40% of the maximal allowable RF power. At the reduced RF power level, the existing natural blood flow may dissipate sufficiently to affect the temperature in the skin. The second or upper temperature limit is primarily a safety limit preventing damage to the skin.


A person treating his own skin with apparatus 100 may simply displace applicator 104 (or apparatus 250) over the skin surface in the segment of skin to be treated at a reasonable speed where the temperature or acceleration feedback will adjust the RF power to obtain the desired treatment result. Known methods of monitoring the skin impedance between electrodes 132 and allowing the temperature of the skin between the electrodes to be followed by changing RF power may be also applied to the present treatment method. It is known that temperatures of about 40 degrees Celsius and lower do not cause the desired skin treatment effect. In cases where the user moves applicator 104 faster than desired, the temperature and acceleration feedback systems adjust the RF power to get a desired treatment effect. An audible signal alerting the user on the desired temperature or acceleration may be generated by a buzzer located in stand 108.


Temperature and acceleration feedback loops automatically adjust the treatment parameters to the electrical properties of the treated person's skin. These feedback loops avoid an undesired rise in temperature of the skin and limit the skin heating. The loops provide signals to the user to indicate the presence of conditions under which the treatment is not effective. Such notice enables the user to correct the treatment parameters. All of these features, or the inclusion of a subset of the described features, when incorporated into an embodiment make apparatus 100 ideal for personal use in residential apartment conditions or the like.


Generally, the user may use and operate apparatus 100 or apparatus 250 according to the present method for skin rejuvenation, collagen remodeling and contraction, skin tightening, wrinkle treatment, subcutaneous tissue treatment, cellulite treatment, pore size reduction, skin texture and tone improvement, acne treatment and hair removal.


The method of skin treatment presented may be further enhanced by applying red and infrared radiation generated by lamp 144 (FIGS. 2 and 6) to the surface of the treated segment of the skin 172. This allows treatment of such skin targets as vascular lesions, varicose veins, acne, and mole marks. The optical energy of the lamp or similar optical energy source may have a value of 1W to 10W and be applied for a time similar to that of RF application. Actually, simultaneous treatment of skin and skin surface may have mutually beneficial effects. It reduces the risk of adverse effects associated with light only based treatment, and use of RF energy is advantageous in treating most skin types since this form of energy is not sensitive to skin pigmentation.


The skin post-treatment process includes at least gel removal from the skin, cleaning the skin surface treated and if necessary application of a moisturizing cream to reduce post treatment effects.


A number of embodiments have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the method. Accordingly, other embodiments are within the scope of the following claims:

Claims
  • 1. A method of skin treatment, said method comprising: a) applying an applicator with at least a pair of electrodes mounted on a distal end of the applicator, to a segment of subject skin to be treated;b) supplying said electrodes with an RF voltage generated by an RF voltage generator with an output stage that includes a transformer with a secondary center tap connected to ground earth through an inductor to obtain a zero potential in the middle of the span of the electrodes with respect to the ground; andc) enabling a contact between said electrodes and said skin and short circuiting said electrodes enabling a RF current to pass through the skin between said electrodes, and moving said applicator in a scanning movement over a segment of the skin to be treated.
  • 2. The method of skin treatment according to claim 1, further comprising a source of light located between the electrodes and configured to apply red and infrared radiation to the same segment of the skin.
  • 3. The method of skin treatment according to claim 1, wherein said RF power is from 1 W to 20 W and has a frequency from 300 kHz to 50 MHz.
  • 4. The method of skin treatment according to claim 1, wherein said RF power is applied in a continuous or quasi-continuous mode for at least 0.5 sec.
  • 5. The method of skin treatment according to claim 1, wherein sensors are sensing at least one of a group of electrode temperature, skin temperature, and skin impedance and wherein the RF power automatically changes, based on input of at least one of said sensors.
  • 6. The method of skin treatment according to claim 5, wherein said automatic changes in the RF power are at least one of the changes of RF duty cycle, RF voltage, switch-off of the RF, and change of scanning speed.
  • 7. The method of skin treatment according to claim 5, wherein said automatic changes in the RF power take place at first skin temperature or at second skin temperature and wherein the first temperature exceeds 44 degrees Celsius and the second temperature exceeds 45 degrees Celsius.
  • 8. The method of skin treatment according to claim 1 including a skin pretreatment method wherein the skin pretreatment method includes at least spreading of gel over the skin segment to be treated and wherein said gel as electrical resistance higher than said treated skin surface.
  • 9. A method of skin treatment, said method comprising: a) applying an applicator with an elongated body a portion of which has been adapted for mounting of at least a pair of electrodes adapted to apply RF energy, generated by an RF voltage generator with an output stage that includes a transformer with a secondary center tap connected to ground earth through an inductor, to a segment of subject skin, such that said skin connects the electrodes enabling an RF current to pass between said electrodes;b) enabling contact between said electrodes and skin and moving said applicator over a segment of the skin to be treated in a scanning movement; andc) applying concurrently with the RF to the same segment of skin red and infrared radiation.
  • 10. The method of skin treatment according to claim 9, further comprising sensing by one or more sensors at least one of a group of electrode temperature, skin temperature, and skin impedance accompanying said treatment and wherein based on input of at least one of said sensors the RF power automatically changes.
  • 11. The method according to claim 10, wherein automatic changes in RF power take place at first temperature when said temperature exceeds 44 degrees Celsius and the second temperature when said temperature exceeds 45 degrees Celsius.
  • 12. The method of skin treatment according to claim 10, further comprising a skin pretreatment process and a skin post-treatment processes.
  • 13. The skin pretreatment method according to claim 12, wherein said method includes at least gel spreading over the skin surface to be treated has electrical resistance higher than said treated skin surface.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is being filed under 35 USC 111 and 37 CFR 1.53(b) as a divisional application to patent application filed in the United States on Feb. 18, 2009 now U.S. Pat. No. 8,606,366 and assigned Ser. No. 12/388,309.

US Referenced Citations (345)
Number Name Date Kind
1430354 Burdick Sep 1922 A
2183726 Sommer et al. Feb 1939 A
2231095 Sommer et al. Feb 1941 A
2824308 Duncan Feb 1958 A
3088205 Ellis May 1963 A
D196532 Facci Oct 1963 S
3925739 Brownell Dec 1975 A
3946738 Newton et al. Mar 1976 A
3964482 Gerstel et al. Jun 1976 A
4016886 Doss et al. Apr 1977 A
4182329 Smit et al. Jan 1980 A
D269294 Rakocy et al. Jun 1983 S
D271015 Geraets Oct 1983 S
D271199 Geraets Nov 1983 S
4444190 Mutzhas Apr 1984 A
D274462 Rakocy et al. Jun 1984 S
4553936 Wang Nov 1985 A
4686986 Fenyo et al. Aug 1987 A
4753958 Weinstein et al. Jun 1988 A
4755361 Fuderer Jul 1988 A
4784135 Blum et al. Nov 1988 A
4837027 Lee et al. Jun 1989 A
4858604 Konishi Aug 1989 A
4867682 Hammesfahr et al. Sep 1989 A
4869584 Dion Sep 1989 A
4943290 Rexroth et al. Jul 1990 A
5016999 Williams May 1991 A
5019034 Weaver et al. May 1991 A
5165418 Tankovich Nov 1992 A
5169384 Bosrnak et al. Dec 1992 A
5196709 Berndt et al. Mar 1993 A
5232441 Stephen et al. Aug 1993 A
5246867 Lakowicz et al. Sep 1993 A
5281825 Berndt et al. Jan 1994 A
5286479 Garlich et al. Feb 1994 A
5316473 Hare May 1994 A
5318514 Hofmann Jun 1994 A
5328478 Mc Vay Jul 1994 A
5380272 Gross Jan 1995 A
5401242 Yacowitz Mar 1995 A
5402697 Brooks Apr 1995 A
5406340 Hoff Apr 1995 A
5409835 Lakowicz et al. Apr 1995 A
5418130 Platz et al. May 1995 A
5421817 Liss et al. Jun 1995 A
5423803 Tankovich et al. Jun 1995 A
5439440 Hofmann Aug 1995 A
5445609 Lattin et al. Aug 1995 A
5445611 Eppstein et al. Aug 1995 A
5458140 Eppstein et al. Oct 1995 A
5462520 Hofmann Oct 1995 A
5464386 Hofmann Nov 1995 A
5485530 Lakowicz et al. Jan 1996 A
5487662 Kipke et al. Jan 1996 A
5500437 Saitoh et al. Mar 1996 A
5521392 Kennedy et al. May 1996 A
5552300 Makrides et al. Sep 1996 A
5571149 Liss et al. Nov 1996 A
5582168 Samuels et al. Dec 1996 A
5582476 Hansen Dec 1996 A
5611793 Wilson et al. Mar 1997 A
5624847 Lakowicz et al. Apr 1997 A
5628310 Rao et al. May 1997 A
5628771 Mizukawa et al. May 1997 A
5631169 Lakowicz et al. May 1997 A
5642997 Gregg et al. Jul 1997 A
5648269 Lakowicz et al. Jul 1997 A
5658148 Neuberger et al. Aug 1997 A
5660997 Spaulding Aug 1997 A
5666543 Gartland Sep 1997 A
5674267 Mir et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5688232 Flower Nov 1997 A
5697896 McNichols et al. Dec 1997 A
5698217 Wilking Dec 1997 A
5698866 Doiron et al. Dec 1997 A
5704935 Pahl et al. Jan 1998 A
5707403 Grove et al. Jan 1998 A
5720772 Eckhouse Feb 1998 A
5722397 Eppstein Mar 1998 A
5722411 Suzuki et al. Mar 1998 A
5735844 Anderson et al. Apr 1998 A
5755753 Knowlton May 1998 A
5759767 Lakowicz et al. Jun 1998 A
5769880 Truckai et al. Jun 1998 A
5792049 Eppstein et al. Aug 1998 A
5814008 Chen et al. Sep 1998 A
5824023 Anderson Oct 1998 A
5836999 Eckhouse et al. Nov 1998 A
5843143 Whitehurst Dec 1998 A
5860421 Eppstein et al. Jan 1999 A
5871469 Eggers et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5885211 Eppstein et al. Mar 1999 A
5902272 Eggers et al. May 1999 A
5911223 Weaver et al. Jun 1999 A
5919219 Knowlton Jul 1999 A
5924981 Rothfritz et al. Jul 1999 A
5938657 Assa et al. Aug 1999 A
5949514 Wargon Sep 1999 A
5954710 Paolini et al. Sep 1999 A
5961543 Waldmann Oct 1999 A
5964726 Korenstein et al. Oct 1999 A
5980898 Plenn et al. Nov 1999 A
5983130 Phipps et al. Nov 1999 A
5983131 Weaver et al. Nov 1999 A
5983135 Avrahami Nov 1999 A
5984915 Loeb et al. Nov 1999 A
5993180 Westerhof et al. Nov 1999 A
6002482 Rothfritz et al. Dec 1999 A
6009344 Flower et al. Dec 1999 A
6022316 Eppstein et al. Feb 2000 A
6024733 Eggers et al. Feb 2000 A
6030399 Ignotz et al. Feb 2000 A
6041253 Kost et al. Mar 2000 A
6045502 Eppstein et al. Apr 2000 A
6050988 Zuck Apr 2000 A
6055451 Bambot et al. Apr 2000 A
6056548 Neuberger et al. May 2000 A
6063108 Salansky et al. May 2000 A
6066134 Eggers et al. May 2000 A
6076012 Swanson et al. Jun 2000 A
6080127 Li et al. Jun 2000 A
6080391 Tsuchiya et al. Jun 2000 A
6081934 Stefanovsky et al. Jul 2000 A
6083196 Trautman et al. Jul 2000 A
6088606 Ignotz et al. Jul 2000 A
6090106 Goble et al. Jul 2000 A
6104952 Tu et al. Aug 2000 A
6107326 Jori Aug 2000 A
6117109 Eggers et al. Sep 2000 A
6132701 Perez et al. Oct 2000 A
6142922 Yoshikawa et al. Nov 2000 A
6142939 Eppstein et al. Nov 2000 A
6148232 Avrahami Nov 2000 A
6159194 Eggers et al. Dec 2000 A
6169224 Heinecke et al. Jan 2001 B1
6173202 Eppstein Jan 2001 B1
6183434 Eppstein Feb 2001 B1
6190609 Chapman et al. Feb 2001 B1
6191110 Jaynes et al. Feb 2001 B1
6192734 Rothfritz et al. Feb 2001 B1
6210402 Olsen et al. Apr 2001 B1
6221095 Van Zuylen et al. Apr 2001 B1
6228078 Eggers et al. May 2001 B1
6231593 Meserol May 2001 B1
6235020 Cheng et al. May 2001 B1
6238391 Olsen et al. May 2001 B1
6251127 Biel Jun 2001 B1
6258319 Hearst et al. Jul 2001 B1
6288498 Cheng Sep 2001 B1
6302874 Zhang et al. Oct 2001 B1
6308413 Westerhof et al. Oct 2001 B1
6339775 Zamanian et al. Jan 2002 B1
6343400 Massholder et al. Feb 2002 B1
6343933 Montgomery et al. Feb 2002 B1
6352506 Eppstein et al. Mar 2002 B1
6353763 George et al. Mar 2002 B1
6406157 Audet Jun 2002 B1
6413268 Hartman Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6433343 Cimino et al. Aug 2002 B1
6440121 Weber et al. Aug 2002 B1
6461567 Hearst et al. Oct 2002 B1
6462070 Hasan et al. Oct 2002 B1
6471716 Pecukonis Oct 2002 B1
6477410 Henley et al. Nov 2002 B1
6487447 Weimann et al. Nov 2002 B1
6493940 Westerhof et al. Dec 2002 B2
6494900 Salansky et al. Dec 2002 B1
6497702 Bernaz Dec 2002 B1
6508785 Eppstein Jan 2003 B1
6508813 Altshuler Jan 2003 B1
6512950 Li et al. Jan 2003 B2
6514243 Eckhouse et al. Feb 2003 B1
6517532 Altshuler et al. Feb 2003 B1
6527716 Eppstein Mar 2003 B1
6530915 Eppstein et al. Mar 2003 B1
6533775 Rizoiu et al. Mar 2003 B1
6558653 Andersen et al. May 2003 B2
6572637 Yamazaki et al. Jun 2003 B1
6594905 Furst et al. Jul 2003 B2
6595947 Mikszta et al. Jul 2003 B1
6597946 Avrahami et al. Jul 2003 B2
6602245 Thiberg Aug 2003 B1
6603998 King et al. Aug 2003 B1
6611706 Avrahami et al. Aug 2003 B2
6611707 Prausnitz et al. Aug 2003 B1
6612819 Furst et al. Sep 2003 B1
6615079 Avrahami Sep 2003 B1
6618620 Freundlich et al. Sep 2003 B1
6632002 Chubb et al. Oct 2003 B1
6637877 Hartley et al. Oct 2003 B1
6662054 Kreindel et al. Dec 2003 B2
6663620 Altshuler et al. Dec 2003 B2
6676655 McDaniel Jan 2004 B2
6678554 Sun et al. Jan 2004 B1
6692456 Eppstein et al. Feb 2004 B1
6702808 Kreindel Mar 2004 B1
6704587 Kumar et al. Mar 2004 B1
6706693 Tang et al. Mar 2004 B1
6708060 Avrahami et al. Mar 2004 B1
6711435 Avrahami Mar 2004 B2
6713291 King et al. Mar 2004 B2
6719754 Underwood et al. Apr 2004 B2
D490156 Fischer et al. May 2004 S
D490526 Jonsen May 2004 S
6743211 Prausnitz et al. Jun 2004 B1
6758845 Weckwerth et al. Jul 2004 B1
6761729 Babaev Jul 2004 B2
6767341 Cho Jul 2004 B2
6770069 Hobart et al. Aug 2004 B1
6773431 Eggers et al. Aug 2004 B2
6780838 Lipton et al. Aug 2004 B2
6795728 Chornenky et al. Sep 2004 B2
RE38634 Westerhof et al. Oct 2004 E
6887260 McDaniel May 2005 B1
6889090 Kreindel May 2005 B2
7006874 Knowlton et al. Feb 2006 B2
7013179 Carter et al. Mar 2006 B2
7062317 Avrahami et al. Jun 2006 B2
7123957 Avrahami Oct 2006 B2
7153298 Cohen Dec 2006 B1
7164942 Avrahami et al. Jan 2007 B2
7234239 Saito et al. Jun 2007 B2
7266414 Cornelius et al. Sep 2007 B2
7275819 Bleau Oct 2007 B2
7314470 Malodobry Jan 2008 B2
7335377 Stern et al. Feb 2008 B2
7363075 Stern et al. Apr 2008 B2
7383084 Stern et al. Jun 2008 B2
7395111 Levin et al. Jul 2008 B2
7415306 Levin et al. Aug 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7494488 Weber Feb 2009 B2
7558625 Levin et al. Jul 2009 B2
7963985 Minamoto et al. Jun 2011 B2
8135475 Kreindel et al. Mar 2012 B2
8157807 Ferren et al. Apr 2012 B2
8202268 Wells et al. Jun 2012 B1
20010006645 Norton et al. Jul 2001 A1
20010051180 Watanabe et al. Dec 2001 A1
20020010412 Eppstein Jan 2002 A1
20020010414 Coston et al. Jan 2002 A1
20020082543 Park et al. Jun 2002 A1
20020091311 Eppstein et al. Jul 2002 A1
20020099308 Bojan et al. Jul 2002 A1
20020104543 Hollander et al. Aug 2002 A1
20020120256 Furuno et al. Aug 2002 A1
20020143373 Courtnage et al. Oct 2002 A1
20020161324 Henley et al. Oct 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020183245 Hasan et al. Dec 2002 A1
20020190337 House et al. Dec 2002 A1
20020193729 Cormier et al. Dec 2002 A1
20020198575 Sullivan Dec 2002 A1
20030017598 Burke et al. Jan 2003 A1
20030032950 Altshuler et al. Feb 2003 A1
20030078499 Eppstein Apr 2003 A1
20030092982 Eppstein May 2003 A1
20030097162 Kreindel May 2003 A1
20030109871 Johnson et al. Jun 2003 A1
20030135250 Lauman et al. Jul 2003 A1
20030139790 Ingle et al. Jul 2003 A1
20030195494 Altshuler et al. Oct 2003 A1
20030199946 Gutwein Oct 2003 A1
20040010250 Manna et al. Jan 2004 A1
20040010298 Altshuler et al. Jan 2004 A1
20040028727 Glenn et al. Feb 2004 A1
20040039342 Eppstein et al. Feb 2004 A1
20040039343 Eppstein et al. Feb 2004 A1
20040064167 Berry et al. Apr 2004 A1
20040133251 Altshuler et al. Jul 2004 A1
20040143308 Lundahl et al. Jul 2004 A1
20040147984 Altshuler et al. Jul 2004 A1
20040167501 Island et al. Aug 2004 A1
20040185055 GIenn et al. Sep 2004 A1
20040193234 Butler Sep 2004 A1
20040210214 Knowlton Oct 2004 A1
20040258703 Glenn et al. Dec 2004 A1
20040260210 Ella et al. Dec 2004 A1
20050015042 Sun et al. Jan 2005 A1
20050043653 Trimmer et al. Feb 2005 A1
20050049543 Anderson et al. Mar 2005 A1
20050119605 Sohn Jun 2005 A1
20050123565 Subramony et al. Jun 2005 A1
20050137654 Hoenig et al. Jun 2005 A1
20050137655 MacFarland et al. Jun 2005 A1
20050143793 Korman et al. Jun 2005 A1
20050147137 Slatkine Jul 2005 A1
20050177139 Yamazaki et al. Aug 2005 A1
20060036300 Kreindel Feb 2006 A1
20060095096 DeBenedictis et al. May 2006 A1
20060149343 Altshuler et al. Jul 2006 A1
20060173518 Kreindel Aug 2006 A1
20060200213 McDaniel Sep 2006 A1
20060206173 Gertner et al. Sep 2006 A1
20060224217 Burgmann et al. Oct 2006 A1
20060231568 Lynn et al. Oct 2006 A1
20060247741 Hsu et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20070009542 Levin et al. Jan 2007 A1
20070016117 Sliwa et al. Jan 2007 A1
20070031495 Eppstein et al. Feb 2007 A1
20070093798 Debenedictis et al. Apr 2007 A1
20070106349 Karni et al. May 2007 A1
20070129711 Altshuler et al. Jun 2007 A1
20070142881 Hennings Jun 2007 A1
20070191821 Boxer Wachler Aug 2007 A1
20070191827 Lischinsky Aug 2007 A1
20070197895 Nycz et al. Aug 2007 A1
20070239143 Altshuler et al. Oct 2007 A1
20070270732 Levin et al. Nov 2007 A1
20070271714 Adam et al. Nov 2007 A1
20070287949 Levin et al. Dec 2007 A1
20070292445 Levin Dec 2007 A1
20080071334 Hoenig et al. Mar 2008 A1
20080114281 Birchall et al. May 2008 A1
20080123238 Campos et al. May 2008 A1
20080208107 McRae et al. Aug 2008 A1
20080214988 Altshuler et al. Sep 2008 A1
20080215124 Wagenaar et al. Sep 2008 A1
20080221504 Aghion Sep 2008 A1
20080274166 Sacks et al. Nov 2008 A1
20080294153 Allshuler et al. Nov 2008 A1
20080306476 Hennings et al. Dec 2008 A1
20090036953 Gustavsson Feb 2009 A1
20090043293 Pankratov et al. Feb 2009 A1
20090105706 Livneh Apr 2009 A1
20090112205 McGill et al. Apr 2009 A1
20090182315 Zigan et al. Jul 2009 A1
20090192503 Epshtein et al. Jul 2009 A1
20090240310 Kennedy Sep 2009 A1
20090264810 Eppstein et al. Oct 2009 A1
20100063565 Beerwerth et al. Mar 2010 A1
20100174224 Sohn Jul 2010 A1
20100198134 Eckhouse Aug 2010 A1
20100274329 Bradley et al. Oct 2010 A1
20100293807 Bar-El et al. Nov 2010 A1
20110137386 Kreindel Jun 2011 A1
20110166559 Eckhouse et al. Jul 2011 A1
20120143270 Mehta Jun 2012 A1
20120290023 Boyden et al. Nov 2012 A1
20130289679 Eckhouse et al. Oct 2013 A1
Foreign Referenced Citations (56)
Number Date Country
2495005 Feb 2004 CA
1078383 Nov 1993 CN
547482 Jun 1993 EP
0743029 Jul 2002 EP
0824019 Nov 2002 EP
2125986 Aug 1982 GB
2202442 Sep 1988 GB
04299998 Oct 1992 JP
06007457 Jan 1994 JP
06113920 Apr 1994 JP
11132843 Dec 1999 JP
2003034630 Feb 2003 JP
WO-9310854 Jun 1993 WO
WO-9321992 Nov 1993 WO
WO-9414062 Jun 1994 WO
WO-9416765 Aug 1994 WO
WO-9427671 Dec 1994 WO
WO-9622808 Jan 1996 WO
WO-9617651 Jun 1996 WO
WO-9640364 Dec 1996 WO
WO-9707734 Mar 1997 WO
WO-9716222 May 1997 WO
WO-9800193 Jan 1998 WO
WO-9829134 Jul 1998 WO
WO-9909143 Feb 1999 WO
WO-9944507 Sep 1999 WO
WO-9944508 Sep 1999 WO
WO-9944637 Sep 1999 WO
WO-9944638 Sep 1999 WO
WO-9944678 Sep 1999 WO
WO-0003758 Jan 2000 WO
WO-0004832 Feb 2000 WO
WO-0015102 Mar 2000 WO
WO-0044438 Aug 2000 WO
WO-0059371 Oct 2000 WO
WO-0074583 Dec 2000 WO
WO-0074763 Dec 2000 WO
WO-0074767 Dec 2000 WO
WO-0076575 Dec 2000 WO
WO-0113989 Mar 2001 WO
WO-0135820 May 2001 WO
WO-02074244 Sep 2002 WO
WO-02078644 Oct 2002 WO
WO-02090210 Nov 2002 WO
WO-03039367 May 2003 WO
WO-03039620 May 2003 WO
WO-2004039426 May 2004 WO
WO-2004039427 May 2004 WO
WO-2004039428 May 2004 WO
WO-2006128034 Nov 2006 WO
WO-2008091878 Jul 2008 WO
WO-2009047774 Apr 2009 WO
WO-2006131931 Jan 2013 WO
WO-03077970 Feb 2013 WO
WO-03101507 Mar 2013 WO
WO-03077971 Dec 2013 WO
Non-Patent Literature Citations (54)
Entry
Acne Clearance, LHE Clinical Casebook, Radiancy: Lighting the Future of Skin Care, © 2002.
Acne Star web page, describing “How to use get rid of Acne Treatment”, printed May 5, 2005.
Acne Star web page, describing Clinical Studies, “The Treatment of acne vulgaris with a novel device that uses Gallium-Nitride diode light”, printed May 5, 2005.
Aesthetic Buyers Guide: The Leading Cosmetic Practice Resource, Jan./Feb. 2004, vol. 7, No. I.
Bollen, CM. et al., “Full- versus partial-mouth disinfection in the treatment of periodontal infections. A pilot study: long-term microbiological observations”. J Clin Periodontol Oct. 1996;23(10):960-70 (Abstract).
Bollen, CM. et al., “The effect of a one-stage full-mouth disinfection on different intra-oral niches. Clinical and microbiological observations”, J Clin Periodontol Jan. 1998;25(1):56-66 (Abstract).
CALDER1-IEAD, R. Glen, “The Photobiology of LED Photothcrapy”.
Charakida et al., “Phototherapy in the Treatment of Acne Vulgaris, What is the Role?”, Am. J. Clin. Dermatol 2004: 5(4): 211-216.
Cohen LR., “What causes bad breath?”, University of Toronto; webpage (printed before Nov. 2, 2004).
Coventry et al. (2000) “ABC of oral health: Periodontal disease” British Medical Journal, 321, 36-39.
De Soete, M. et al., “One-stage full-mouth disinfection. Long-term microbiological results analyzed by checker board DNA-DNA hybridization”, J Periodontol Mar. 2001; 72(3):374-82 (Abstract).
Elman M. et al., “The effective treatment of acne vulgaris by a high-intensity, narrow bank 405-420 nm light source”, Cosmetic & Laser Ther 2003; 5: 111-116.
Flow Control Network web page, “Mini Diaphragm Pumps for Precision Dispensing” by Ping Lin, printed Aug. 2, 2005.
Friedberg JS et al., “Antibody-Targeted Photolysis Bacteriocidal Effects of Sn (IV) Chlonn e6-Dextran-Monoclonal Antibody Conjugates”, Annals New York Academy of Sciences 618:383-393, 1991.
Greenstein G., Full-mouth therapy versus individual quadrant root planning: a critical commentary, JPeriodontol Jul. 2002;73(7):797-812 (Abstract).
Hamblin, M. et al., “Rapid Control of Wound Infections by Targeted Photodynamic Therapy Monitored by In Vivo Bioluminescence Imagining”, Photochemistry and Photobiology, 2002, 75(1 ): 51-57.
Komerik et al. (2003) “In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated photosensitization in an animal model” Antimicrobial Agents and Chemotherapy, 47(3), 932-940.
Krespi, et al. (2005) “Lethal photosensitization of oral pathogens via red-filtered halogen lamp” Oral Diseases, 11(S1 ), 92-95.
Malik, Z. et al., “New Trends in Photobiology (Invited Review) Bactericidal Effects of Photoactivated Porphyrins—An Alternative Approach to Antimicrobial Drugs”, Journal of Photochemistry and Photobiology, B: Biology, 5—1—1990}—281-293.
Matevski D. et al., “Lethal photosensitization of periodontal pathogens by a red-filtered Xenon lamp in invitro”, JPeriodont. Res. 2003. 38:428-435.
Matevski D. et al., “Sensitivity of Porphyromonas gingivalis to Light-Activated Toluidine Blue 0”, University of Toronto, Faculty of Dentistry; Slide presentation (presented before Nov. 15, 2002).
Meisel etal. (2005) “Photodynamic therapy for periodontal diseases: State of the are” J. Photochem. Photobiol., 79, 159-170.
Mongardini, C. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. I. Long-term clinical observations”, J Periodontol Jun. 1999;70(6):632-45 lAbstrac!2.—.
Morton C.A. et al., An open study to determine the efficacy of blue light in the treatment of mild to moderate acne: preliminary data (publication status unknown).
Nakano et al. (2002) “Correlation between oral malodor and periodontal bacteria” Microbes Infect., 4(6), 679-683.
Ondine Biopharma web page—printed Oct. 15, 2002.
Papageorgiou et al., “Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris”, British Journal of Dermatology 2000: 142: 973-978.
Pharmaceutical description, Levulan® Kerastick aminolevulinic acid I-IC!) for Topical Solution, 20′X.
Quirynen, M. et al. “Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations”, J Dent Res Aug. 1995;74(8):1459-67 (Abstract).
Quirynen, M. et al., “The effect of a 1-stage full-mouth disinfection on oral malodor and microbial colonization of the tongue in periodontitis. A pilot study”, J Periodontol Mar. 1998;69(3):374-82 (Abstract).
Quirynen, M. et al., “The intra-oral translocation of periodontopathogens jeopardises the outcome of periodontal therapy”, Journal of Clincial Periodontology, Jun. 2001, vol. 28, Issue 6, p. 499 (Abstract).
Quirynen, M. et al., “The role of chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adult periodontitis. Long-term clinical and microbiological observations”, J Clin Periodontol 2000 Al!JL2˜579-89 J—Abstrac—!).
Quirynen. M. et al., “One stage full- versus partial-mouth disinfection in the treatment of chronic adult or generalized early-onset periodontitis. II. Long-term impact on microbial load”, J Periodontol Jun. 1999;70(6):646-56 J—Abstrac!2.—.
Sanz et al. (2001) “Fundamentals of breath malodour” Journal of Contemporary Dental Practice, 2(4), 1-13.
Sarkar et al. (1993) “Lethal photosensitization of bacteria in subgingival plaque from patients with chronic periodontitis” J. Periodont. Res , 28, 204-21 O.
Skin91 I .corn web page regarding Peter Thomas Roth Clinical Acne Medication, acne treatrnent-Benzoyl Peroxide 5% pbp5, printed Apr. 19, 2005.
Soukos et al. (1998) “Targeted antimicrobial photochemotherapy”, Antimicrobial Agents and Chemotherapy 42( 10 ), 2595-2601.
Spire Awarded Contract for Ear Surgery Laser—Press Release Aug. 23, 2002.
Temperatures.corn web page, “Thermistor Temperature Sensors,” printed Aug. 2, 200.
Vandekerckhove, BN. et al.. “Full- versus partial-mouth disinfection in the treatment of periodontal infections. Long-term clinical observations of a pilot study”, J Periodontol Dec. 1996;67(12):1251-9 (Abstract).
Wainwright M., Photodynamic antimicrobial chemotherapy (PACT), Journal of Antimicrobial Chemotherapy (1998) 42, 13-28.
Wilson (2005) “Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infection” Photochem. Photobiol. Sci., 3, 412-418.
Wilson et al. (1995) “Bacteria in supragingival plaque samples can be killed by low-power laser light in the presence of a photosensitizer” J. Appl. Bacteriol., 78, 569-574.
Wood, et al. (1999) “An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biofilrns formed in vivo” J. Photochem. Photogiol. B: Biol., 50, 1-7.
www.lightbioscience.com web page, Gentle Waves Cosmcceuticals, printed Jul. 29, 200.
www.lightbioscience.com web page, Gentle Waves LED Photomodulation Fact Sheet, printed Jul. 29, 2005.
Sintov et al., J. of Controlled Release, 89: 311-320 (2003).
Henry, S. et al., “Micromachined Needles for the Transfermal Delivery of Drugs”, IEEE 11th Annual International Workshop on Micro-Electric-Mechanical Systems, 1998, pp. 494-498.
Chizmadzhev, Yuri A., et al., “Electrical Properties of Skin at Moderate Voltages: Contribution of Appendageal Macropores”, Biophysical Journal, Feb. 1998, vol. 74, pp. 843-856.
“Instructions Manual for the Force 2 Electrosurgical Generator”, Valleylab/TycoHealthcare Group LP, Boulder, Colorado 1999.
PCT/IL11/00256 International Search Report.
PCT/IL11/00170 International Search Report.
PCT/IL10/00751 International Search Report.
PCT/IL2006/00679 International Search Report.
Related Publications (1)
Number Date Country
20110264173 A1 Oct 2011 US
Divisions (1)
Number Date Country
Parent 12388309 Feb 2009 US
Child 13177509 US